A research consortium led by CCS director Prof. Richard Greil and Prof. Michael Gnant (Med. University Vienna) published results on the risk and benefit of extended aromatase inhitor therapy of ER+ breast cancer patients in The New England Journal of Medicine. The clinical study by Gnant et al. revealed that extending hormone therapy by 5 years provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture. Read the full article in NEJM or watch the quick take summary.